CogState (ASX:CGS) share price crashes 20% on quarterly update

CogState shares tanked today despite the company reporting record-breaking results.

| More on:
A man looks stunned as a cloud explodes from his head representing the CogState share price crashing today in

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CogState share price fell as low as $1.84 today — 20% down on yesterday's close
  • The neuroscience technology company released a quarterly update today
  • Clinical sale contracts have increased by 141%, hitting a new record

The CogState Limited (ASX: CGS) share price flatlined today after the company released a business and investor update this morning.

At market close, the CogState share price was down 15.95% to $1.95. The share price bounced back in late afternoon trade after declining to an intraday low of $1.84.

Whilst CogState reported record figures for contracts and revenue, its shares continued the bleeding today as they have all month. The CogState share price began 2022 at $2.55 on the first day of ASX trading on 4 January. That's a 23% dip to date.

So what exactly did CogState report? Let's take a closer look.

CogState investors unenthused by results

CogState aims to provide tools to measure brain health and cognition in order to assist in research and remedies.

Today's announcement reveals just a small number of business financials, with a more detailed report set to be released on 24 February.

CogState's business update revealed:

  • Revenue for 2Q22 up 40% at $10.8 million against its prior corresponding period (PCP)
  • Revenue for 1H22 up 67% at $23.1 million compared to PCP
  • $24.6 million in net cash as of 31 December

Record figures for CogState

In its investor report, CogState revealed a number of records hit during the quarter, including:

  • A 141% increase in executed clinical sale contracts amounting to $54.5 million
  • A 78% increase in contracted future revenue at $132.9 million
  • A 67% increase in group revenue at $23.1 million

The company said Alzheimer's trials have continued to boost its clinical sales contracts. In 1H22, the disease accounted for 90% of CogState sales contracts.

What else is news?

Just recently, CogState announced that its brain assessment tool, CogMate, is to be marketed in Taiwan and Hong Kong through its Taiwanese subsidiary, Eisai Taiwan Inc.

CogMate is a multilingual tool that measures cognitive performance. It can be used with smartphones and other smart devices.

CogState hopes the product will assist in the "self assessment and prevention" of diseases such as dementia, with ageing populations in mind.

Exposure to other countries, including Singapore, is on the horizon.

CogState share price snapshot

Over the past 12 months, the CogState share price has leapt 75%.

There was a 50% jump in June after the company announced its Alzheimer's therapeutic had received accelerated approval based on its clinical trials. At that time, the CogState share price was $1.40. It also saw a sharp 8% jump in September to $1.87.

The company has a market capitalisation of just over $402 million and a price-to-earnings ratio (P/E) of 55.25.

Motley Fool contributor Alice de Bruin has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »